Tuberkulose im Erwachsenenalter

Tom Schaberg; Folke Brinkmann; Cornelia Feiterna-Sperling; Hilte Geerdes-Fenge; Pia Hartmann; Brit Häcker; Barbara Hauer; Walter Haas; Jan Heyckendorf; Christoph Lange; Florian P. Maurer; Albert Nienhaus; Ralf Otto-Knapp; Martin Priwitzer; Elvira Richter; Helmut J.F. Salzer; Otto Schoch; Nicolas Schönfeld; Ralf Stahlmann; Torsten Bauer

doi:10.1055/a-1934-8303

Pneumologie 2022; 76(11): 727-819
DOI: 10.1055/a-1934-8303

Leitlinie

Tuberkulose im Erwachsenenalter

Eine S2k-Leitlinie zur Diagnostik und Therapie, Chemoprävention und Chemoprophylaxe der Tuberkulose im Erwachsenenalter des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose e. V. (DZK) und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. (DGP)^[*] Tuberculosis in adulthoodThe Sk2-Guideline of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of adult tuberculosis patients

Autoren

Tom Schaberg

¹Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose e. V. (DZK), Berlin
Folke Brinkmann

²Abteilung für pädiatrische Pneumologie/CF-Zentrum, Universitätskinderklinik der Ruhr-Universität Bochum, Bochum
Cornelia Feiterna-Sperling

³Klinik für Pädiatrie mit Schwerpunkt Pneumologie, Immunologie und Intensivmedizin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu Berlin, Berlin
Hilte Geerdes-Fenge

⁴Zentrum für Innere Medizin, Universitätsmedizin Rostock
Pia Hartmann

⁵Labor Dr. Wisplinghoff Köln, Klinische Infektiologie, Köln

⁶Department für Klinische Infektiologie, St. Vinzenz-Hospital, Köln
Brit Häcker

¹Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose e. V. (DZK), Berlin
Barbara Hauer

⁷Robert Koch-Institut, Berlin
Walter Haas

⁷Robert Koch-Institut, Berlin
Jan Heyckendorf

⁸Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel
Christoph Lange

⁹Klinische Infektiologie, Forschungszentrum Borstel

¹⁰Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hamburg-Lübeck-Borstel-Riems

¹¹Respiratory Medicine and International Health, Universität zu Lübeck, Lübeck

¹²Baylor College of Medicine and Texas Childrenʼs Hospital, Global TB Program, Houston, TX, USA
Florian P. Maurer

¹³Nationales Referenzzentrum für Mykobakterien, Forschungszentrum Borstel, Borstel

¹⁴Institut für Medizinische Mikrobiologie, Virologie und Hygiene, Universitätsklinikum Hamburg-Eppendorf, Hamburg
Albert Nienhaus

¹⁵Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP), Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg
Ralf Otto-Knapp

¹Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose e. V. (DZK), Berlin
Martin Priwitzer

¹⁶Gesundheitsamt, Landeshauptstadt Stuttgart
Elvira Richter

¹⁷MVZ Labor Dr. Limbach & Kollegen GbR, Heidelberg
Helmut J.F. Salzer

¹⁸Kepler Universitätsklinikum, Linz, Österreich
Otto Schoch

¹⁹Kantonsspital St. Gallen, Schweiz
Nicolas Schönfeld

²⁰Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin
Ralf Stahlmann

²¹Institut für klinische Pharmakologie und Toxikologie, Charité Universitätsmedizin, Berlin
Torsten Bauer

¹Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose e. V. (DZK), Berlin

²⁰Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin

Abstract

Zusammenfassung

Die Tuberkulose ist in Deutschland eine seltene, überwiegend gut behandelbare Erkrankung. Weltweit ist sie eine der häufigsten Infektionserkrankungen mit ca. 10 Millionen Neuerkrankungen/Jahr. Auch bei einer niedrigen Inzidenz in Deutschland bleibt Tuberkulose insbesondere aufgrund der internationalen Entwicklungen und Migrationsbewegungen eine wichtige Differenzialdiagnose. In Deutschland besteht, aufgrund der niedrigen Prävalenz der Erkrankung und der damit verbundenen abnehmenden klinischen Erfahrung, ein Informationsbedarf zu allen Aspekten der Tuberkulose und ihrer Kontrolle. Diese Leitlinie umfasst die mikrobiologische Diagnostik, die Grundprinzipien der Standardtherapie, die Behandlung verschiedener Organmanifestationen, den Umgang mit typischen unerwünschten Arzneimittelwirkungen, die Besonderheiten in der Diagnostik und Therapie resistenter Tuberkulose sowie die Behandlung bei TB-HIV-Koinfektion. Sie geht darüber hinaus auf Versorgungsaspekte und gesetzliche Regelungen wie auch auf die Diagnosestellung und präventive Therapie einer latenten tuberkulösen Infektion ein. Es wird ausgeführt, wann es der Behandlung durch spezialisierte Zentren bedarf.

Die Aktualisierung der S2k-Leitlinie „Tuberkulose im Erwachsenenalter“ soll allen in der Tuberkuloseversorgung Tätigen als Richtschnur für die Prävention, die Diagnose und die Therapie der Tuberkulose dienen und helfen, den heutigen Herausforderungen im Umgang mit Tuberkulose in Deutschland gewachsen zu sein.

Abstract

In Germany tuberculosis is a rare disease and usually well treatable. Worldwide it is one of the most common infectious diseases with approximately 10 million new cases every year.

Even with low incidences in Germany, tuberculosis is an important differential diagnosis especially due to international developments and migration movements. With a decreasing experience there’s a continuous demand on accurate and up-to-date information. This guideline covers all aspects of microbiological diagnostics, basic principles of standard therapy, treatment of extrapulmonary tuberculosis, management of side effects, special features of diagnosis and treatment of resistant tuberculosis, and treatment in TB-HIV coinfection. Also, it explains when treatment in specialized centers is required, aspects of care and legal regulations and the diagnosis and preventive therapy of latent tuberculosis infection.

The update of the S2k guideline “Tuberculosis in Adults” is intended to serve as a guideline for prevention, diagnosis, and treatment of tuberculosis for all those involved in tuberculosis care and to help meet the current challenges in dealing with tuberculosis in Germany.

Volltext

Referenzen

Literatur
1 World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis – 2011 update. Geneva: World Health Organization; 2011
2 World Health Organization. Guidelines for treatment of tuberculosis. 4. Aufl.. Geneva: World Health Organization; 2010
3 Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (DZK). Tuberkulosescreening bei Schwangeren im Kontext von §36 (4) Infektionsschutzgesetz (IfSG). Pneumologie 2016; 70: 777-780
4 Richter E, Andreas S, Diel R. et al. MIQ 05: Tuberkulose Mykobakteriose. In: Podbielski A, Becker K, Kniehl E, Mauch H, Rüssmann H, Schubert S, Zimmermann S. Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. 3. Aufl.. München und Jena: Urban & Fischer/Elsevier; 2019
5 DIN 58943-4 Beiblatt 1: 2011-03. Medizinische Mikrobiologie – Tuberkulosediagnostik – Teil 4: Primärproben zur Tuberkulose- und Mykobakteriosediagnostik – Qualitative und quantitative Anforderungen, Gewinnung, Transport und Aufbewahrung. Berlin: Beuth Verlag; 2011
6 Schoch O, Barben J, Berger C. et al. Tuberculosis in Switzerland: guidance for healthcare professionals. Bern: Swiss Lung Association, Swiss Federal Office of Public Health; 2019
7 National Institute for Health and Care Excellence. Tuberculosis: NICE guideline 33. In. 2016 ed: National Institute for Health and Care Excellence. 2019
8 Davis JL, Cattamanchi A, Cuevas LE. et al. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13: 147-154
9 Nahid P, Dorman SE, Alipanah N. et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63: e147-e195
10 Malekmohammad M, Marjani M, Tabarsi P. et al. Diagnostic yield of post-bronchoscopy sputum smear in pulmonary tuberculosis. Scand J Infect Dis 2012; 44: 369-373
11 Bodal VK, Bal MS, Bhagat S. et al. Fluorescent microscopy and Ziehl-Neelsen staining of bronchoalveolar lavage, bronchial washings, bronchoscopic brushing and post bronchoscopic sputum along with cytological examination in cases of suspected tuberculosis. Indian J Pathol Microbiol 2015; 58: 443-447
12 DIN 58943-32:2015-05. Medizinische Mikrobiologie – Tuberkulosediagnostik – Teil 32: Mikroskopische Methoden zum Nachweis von Mykobakterien. Berlin: Beuth-Verlag; 2015
13 DIN 58943-4:2009-02, Medizinische Mikrobiologie – Tuberkulosediagnostik – Teil 4: Primärproben zur Tuberkulose- und Mykobakteriosediagnostik – Qualitative und quantitative Anforderungen, Gewinnung, Transport und Aufbewahrung – Beiblatt 1: Verhütung von Kontaminationen der Patientenproben mit Mykobakterien bei der Aufarbeitung im Labor. 2011-03.
14 Ziegler R, Just HM, Castell S. et al. Infektionsprävention bei Tuberkulose – Empfehlungen des DZK. Pneumologie 2012; 66: 269-282
15 Diel R, Loytved G, Nienhaus A. et al. Neue Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose. Pneumologie 2011; 65: 359-378
16 Pfyffer G. Mycobacterium: general characteristics, laboratory detection and staining procedures. rgensen M, Pfaller M, Carroll K. et al. Manual of Clinical Microbiology. Washington: ASM Press; 2015: 536-569
17 DIN 58943-3:2011-03. Medizinische Mikrobiologie – Tuberkulosediagnostik – Teil 3: Kulturelle Methoden zum Nachweis von Mykobakterien. Berlin: Beuth-Verlag; 2011
18 Cirillo DM, Cabibbe AM, De Filippo MR. et al. Use of WGS in Mycobacterium tuberculosis routine diagnosis. Int J Mycobacteriol 2016; 5 (Suppl. 01) S252-S253
19 Palomino JC. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 2009; 56: 103-111
20 World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection. Geneva: World Health Organization; 2020
21 Zifodya JS, Kreniske JS, Schiller I. et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev 2021; 2: Cd009593
22 Kohli M, Schiller I, Dendukuri N. et al. Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2021; 1: Cd012768
23 Stellmacher F, Kirfel J, Kalsdorf B. et al. Molekularpathologie der Tuberkulose: Stellenwert, Methodik und Grenzen. Pathologe 2021; 42: 78-82
24 Stellmacher F, Perner S. Histopathologie der Lungentuberkulose. Pathologe 2021; 42: 71-77
25 World Health Organization. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children: Policy Update. Geneva: World Health Organization; 2013
26 World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva: World Health Organization; 2021
27 Glasauer S, Altmann D, Hauer B. et al. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017. PLoS One 2019; 14: e0217597
28 Kohli M, MacLean E, Pai M. et al. Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis. Eur Respir J 2021; 57: 2000747
29 World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, 27–29 October 2020.
30 Bonnet I, Enouf V, Morel F. et al. A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB((R)) Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Front Cell Infect Microbiol 2021; 11: 707244
31 Jouet A, Gaudin C, Badalato N. et al. Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs. Eur Respir J 2021; 57: 2002338
32 DIN 58943-8:2009-04. Medizinische Mikrobiologie – Tuberkulosediagnostik – Teil 8: Empfindlichkeitsprüfung von Tuberkulosebakterien gegen Chemotherapeutika. Berlin: Beuth-Verlag; 2009
33 Horne DJ, Pinto LM, Arentz M. et al. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. J Clin Microbiol 2013; 51: 393-401
34 Van Deun A, Aung KJ, Bola V. et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633-2640
35 Miotto P, Cabibbe AM, Borroni E. et al. Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis. J Clin Microbiol 2018; 56: e01599-17
36 World Health Organization. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO
37 World Health Organisation. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018. (WHO/CDS/TB/2018.5). Licence: CC BY-NC-SA 3.0 IGO. 2018
38 World Health Organization. WHO operational handbook on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO
39 Fenner L, Egger M, Bodmer T. et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 3047-3053
40 Otto-Knapp R, Vesenbeckh S, Schonfeld N. et al. Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation. Int J Tuberc Lung Dis 2016; 20: 1275-1276
41 Andres S, Gröschel MI, Hillemann D. et al. A Diagnostic Algorithm To Investigate Pyrazinamide and Ethambutol Resistance in Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Low-Incidence Setting. Antimicrob Agents Chemother 2019; 63: e01798-18
42 Ramirez-Busby SM, Valafar F. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2015; 59: 5267-5277
43 Farhat MR, Jacobson KR, Franke MF. et al. Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. J Clin Microbiol 2016; 54: 727-733
44 Avalos E, Catanzaro D, Catanzaro A. et al. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One 2015; 10: e0120470
45 Kadura S, King N, Nakhoul M. et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother 2020; 75: 2031-2043
46 Andres S, Merker M, Heyckendorf J. et al. Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon. Am J Respir Crit Care Med 2020; 201: 1564-1568
47 Polsfuss S, Hofmann-Thiel S, Merker M. et al. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment. Clin Infect Dis 2019; 69: 1229-1231
48 Vilcheze C, Jacobs Jr WR. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. Microbiol Spectr 2014; 2: MGM2-0014-2013
49 Diel R, Kohl TA, Maurer FP. et al. Accuracy of whole-genome sequencing to determine recent tuberculosis transmission: an 11-year population-based study in Hamburg, Germany. Eur Respir J 2019; 54: 1901154
50 Tagliani E, Anthony R, Kohl TA. et al. Use of a whole genome sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017–2019: an ECDC pilot study. Eur Respir J 2021; 57: 2002272
51 Nikolayevskyy V, Niemann S, Anthony R. et al. Role and value of whole genome sequencing in studying tuberculosis transmission. Clin Microbiol Infect 2019; 25: 1377-1382
52 Lee RS, Behr MA. The implications of whole-genome sequencing in the control of tuberculosis. Ther Adv Infect Dis 2016; 3: 47-62
53 Robert Koch-Institut. PHIMS-TB: Aufbau einer integrierten molekularen Surveillance am Beispiel der Tuberkulose. Stand (11.10.2022): https://www.rki.de/DE/Content/InfAZ/T/Tuberkulose/imstb.html
54 Bös L, Kröger S, Niemann S. et al. Epidemiologisches Bulletin 11/2021. Vorstellung des Projektes „Public-Health-Beitrag einer bundesweiten integrierten molekularen Surveillance am Beispiel der Tuberkulose (PHIMS-TB).
55 World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017
56 Nahid P, Mase SR, Migliori GB. et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. AJRCCM 2019; 200: e93-e142
57 World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO
58 Horsburgh Jr CR, Barry 3rd CE, Lange C. Treatment of Tuberculosis. N Engl J Med 2015; 373: 2149-2160
59 Velásquez GE, Brooks MB, Coit JM. et al. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med 2018; 198: 657-666
60 World Health Organisation. Treatment of drug-susceptible TB: rapid communication. Geneva: WHO; 2021
61 Gallardo CR, Rigau Comas D, Valderrama Rodriguez A. et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2016;
62 Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010. Eur Respir J 2011; 37: 441-462
63 Blumberg HM, Burman WJ, Chaisson RE. et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662
64 World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO
65 Milburn H, Ashman N, Davies P. et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010; 65: 557-570
66 Milburn HJ. How should we treat tuberculosis in adult patients with chronic kidney disease? Key messages from the British Thoracic Society Guidelines. Pol Arch Med Wewn 2010; 120: 417-422
67 National HIV & TB HCW Hotline MIC, Division of Clinical Pharmacology, Faculty of Health Sciences, University of Cape Town. Management of suspected drug-induced rash, kidney injury and liver injury in adult patients on TB treatment and/or antiretroviral treatment. Cape Town: University of Cape Town; 2018
68 Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707
69 Diel R, Schaberg T, Nienhaus A. et al. Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals. Pneumologie 2021;
70 Winthrop KL, Mariette X, Silva JT. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018; 24 (Suppl. 02) S21-S40
71 Solovic I, Sester M, Gomez-Reino JJ. et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206
72 Diel R, Hauer B, Loddenkemper R. et al. Empfehlungen für das Tuberkulosescreening vor Gabe von TNF-α-Inhibitoren bei rheumatischen Erkrankungen. Pneumologie 2009; 63: 329-334
73 Singh JA, Wells GA, Christensen R. et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 2011: CD008794
74 Zhang Z, Fan W, Yang G. et al. Risk of tuberculosis in patients treated with TNF-alpha antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017; 7: e012567
75 Maxwell LJ, Zochling J, Boonen A. et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015;
76 Sundbaum JK, Arkema EV, Bruchfeld J. et al. Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics. J Rheumatol 2021; 48: 1243-1250
77 Cantini F, Prignano F, Goletti D. Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. J Rheumatol Suppl 2014; 91: 78-82
78 Suh YS, Kwok SK, Ju JH. et al. Safe re-administration of tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFalpha therapy. J Korean Med Sci 2014; 29: 38-42
79 Kim YJ, Kim YG, Shim TS. et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford) 2014; 53: 1477-1481
80 Grim SA, Layden JE, Roth P. et al. Latent tuberculosis in kidney and liver transplant patients: a review of treatment practices and outcomes. Transpl Infect Dis 2015; 17: 768-777
81 Bumbacea D, Arend SM, Eyuboglu F. et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 2012; 40: 990-1013
82 Adamu B, Abdu A, Abba AA. et al. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. Cochrane Database of Systematic Reviews 2014;
83 Hong Kong Chest Service. A controlled clinical comparison of 6 and 8 month of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 1991; 143: 262-267
84 Chung CL, Huang WC, Huang HL. et al. Subsequent Antituberculous Treatment May Not Be Mandatory Among Surgically Resected Culture-Negative Pulmonary Granulomas: A Retrospective Nationwide Multicenter Cohort Study. Open Forum Infect Dis 2021; 8: ofab565
85 Wang C, Liu Y, Lin H. et al. The Necessity of Anti-Tuberculosis Therapy after Resection of Pulmonary Tuberculous Nodules: A Single Center Retrospective Study. Ann Thorac Cardiovasc Surg 2020; 26: 190-195
86 Laisaar T, Viiklepp P, Hollo V. Long-term follow-up after thoracoscopic resection of solitary pulmonary tuberculoma. Indian J Tuberc 2014; 61: 51-56
87 Hsu KY, Lee HC, Ou CC. et al. Value of video-assisted thoracoscopic surgery in the diagnosis and treatment of pulmonary tuberculoma: 53 cases analysis and review of literature. J Zhejiang Univ Sci B 2009; 10: 375-379
88 Bothamley G. Drug treatment for tuberculosis during pregnancy: safety considerations. Drug Saf 2001; 24: 553-565
89 Feiterna-Sperling C, Brinkmann F, Adamczick C. et al. S2k-Leitlinie zur Diagnostik, Prävention und Therapie der Tuberkulose im Kindes- und Jugendalter. Pneumologie 2017; 71: 629-680
90 Loveday M, Hlangu S, Furin J. Breastfeeding in women living with tuberculosis. Int J Tuberc Lung Dis 2020; 24: 880-891
91 Caminero JA, Lasserra P, Piubello A. et al. Adverse anti-tuberculosis drug events and their management. Migliori GB, Bothamley G, Duarte R, Rendon A. Tuberculosis. Sheffield, UK: ERS; 2018: 205-227
92 Saukkonen JJ, Cohn DL, Jasmer RM. et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952
93 Jong E, Conradie F, Berhanu R. et al. Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB. Southern African Journal of HIV Medicine 2013; 14: 113
94 Hickey AJ, Gounder L, Moosa MY. et al. A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection. BMC Infect Dis 2015; 15: 209
95 Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. MMWR 2003; 52: 735-739
96 Lehloenya RJ, Dheda K. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Rev Anti Infect Ther 2012; 10: 475-486
97 Kobashi Y, Abe T, Shigeto E. et al. Desensitization therapy for allergic reactions to antituberculous drugs. Intern Med 2010; 49: 2297-2301
98 Bermingham WH, Bhogal R, Arudi Nagarajan S. et al. Practical management of suspected hypersensitivity reactions to anti-tuberculosis drugs. Clin Exp Allergy 2022; 52: 375-386
99 Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983; 5 (Suppl. 03) S440-S450
100 Chatterjee VK, Buchanan DR, Friedmann AI. et al. Ocular toxicity following ethambutol in standard dosage. Br J Dis Chest 1986; 80: 288-291
101 Matsumoto T, Kusabiraki R, Arisawa A. et al. Drastically Progressive Ethambutol-induced Optic Neuropathy after Withdrawal of Ethambutol: A Case Report and Literature Review. Intern Med 2021; 60: 1785-1788
102 Kumar A, Sandramouli S, Verma L. et al. Ocular ethambutol toxicity: is it reversible?. J Clin Neuroophthalmol 1993; 13: 15-17
103 Menon V, Jain D, Saxena R. et al. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol 2009; 93: 1251-1254
104 Keeping JA, Searle CW. Optic neuritis following isoniazid therapy. Lancet 1955; 269: 278
105 Karmon G, Savir H, Zevin D. et al. Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment. Ann Ophthalmol 1979; 11: 1013-1017
106 Snider Jr DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980; 61: 191-196
107 Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. British journal of clinical pharmacology 2016; 81: 412-419
108 Doherty AM, Kelly J, McDonald C. et al. A review of the interplay between tuberculosis and mental health. Gen Hosp Psychiatry 2013; 35: 398-406
109 Ben Salem C, Slim R, Fathallah N. et al. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford) 2017; 56: 679-688
110 Bruguerolle B. Chronopharmacokinetics. Current status. Clin Pharmacokinet 1998; 35: 83-94
111 Tang Y, Zhang J, Huang H. et al. Pleural IFN-γ release assay combined with biomarkers distinguished effectively tuberculosis from malignant pleural effusion. BMC Infect Dis 2019; 19: 55
112 Ryan H, Yoo J, Darsini P. Corticosteroids for tuberculous pleurisy. Cochrane Database Syst Rev 2017; 3: CD001876
113 Evans DJ. The use of adjunctive corticosteroids in the treatment of pericardial, pleural and meningeal tuberculosis: do they improve outcome?. Respir Med 2008; 102: 793-800
114 Sellar RS, Corbett EL, DʼSa S. et al. Therapie einer Lymphknotentuberkulose. Praxis (Bern 1994) 2010; 99: 1043-1046
115 Daley CL, Iaccarino JM, Lange C. et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71: 905-913
116 Barr DA, Coussens AK, Irvine S. et al. Paradoxical upgrading reaction in extra-pulmonary tuberculosis: association with vitamin D therapy. Int J Tuberc Lung Dis 2017; 21: 677-683
117 Geerdes-Fenge HF, Pongratz P, Liese J. et al. Vacuum-assisted closure therapy of paradoxical reaction in tuberculous lymphadenopathy caused by Mycobacterium africanum. Infection 2018; 46: 427-430
118 Cek M, Lenk S, Naber KG. et al. EAU guidelines for the management of genitourinary tuberculosis. Eur Urol 2005; 48: 353-362
119 Almadi MA, Ghosh S, Aljebreen AM. Differentiating intestinal tuberculosis from Crohnʼs disease: a diagnostic challenge. Am J Gastroenterol 2009; 104: 1003-1012
120 Jullien S, Jain S, Ryan H. et al. Six-month therapy for abdominal tuberculosis. Cochrane Database Syst Rev 2016; 11: CD012163
121 Wiysonge CS, Ntsekhe M, Thabane L. et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev 2017; 9: CD000526
122 Syed FF, Mayosi BM. A modern approach to tuberculous pericarditis. Prog Cardiovasc Dis 2007; 50: 218-236
123 National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. NICE clinical guideline 117. London: National Institute for Health and Care Excellence NICE; 2011
124 Nau R, Prange HW, Menck S. et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29: 719-724
125 Leen WG, Willemsen MA, Wevers RA. et al. Cerebrospinal fluid glucose and lactate: age-specific reference values and implications for clinical practice. PLoS One 2012; 7: e42745
126 Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23: 858-883
127 Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis (Edinb) 2010; 90: 375-392
128 Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) 2010; 90: 279-292
129 Heemskerk AD, Bang ND, Mai NT. et al. Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis. N Engl J Med 2016; 374: 124-134
130 Thwaites G, Fisher M, Hemingway C. et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009; 59: 167-187
131 Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2016; 4: CD002244
132 Davis AG, Donovan J, Bremer M. et al. Host Directed Therapies for Tuberculous Meningitis. Wellcome Open Res 2020; 5: 292
133 Marais BJ, Cheong E, Fernando S. et al. Use of Infliximab to Treat Paradoxical Tuberculous Meningitis Reactions. Open Forum Infect Dis 2021; 8: ofaa604
134 Babjuk M, Burger M, Zigeuner R. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013; 64: 639-653
135 Rischmann P, Desgrandchamps F, Malavaud B. et al. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 2000; 37 (Suppl. 01) 33-36
136 Witjes F, Palou J, Soloway M. et al. Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy – Associated Adverse Events. European Urology supplements 2008; 7: 667-674
137 Durek C, Rusch-Gerdes S, Jocham D. et al. Interference of modern antibacterials with bacillus Calmette-Guerin viability. J Urol 1999; 162: 1959-1962
138 Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992; 19: 565-572
139 Lamm DL, van der Meijden PM, Morales A. et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992; 147: 596-600
140 Rastogi N, Goh KS, Bryskier A. et al. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 1610-1616
141 Durek C, Jurczok A, Werner H. et al. Optimal treatment of systemic bacillus Calmette-Guerin infection: investigations in an animal model. J Urol 2002; 168: 826-831
142 Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170: 964-969
143 Geerdes-Fenge HF, Stubbe F, Lobermann M. et al. BCGitis mit Lungen-, Leber- und Knochenmarksbeteiligung nach Immuntherapie eines Urothelkarzinoms. Dtsch Med Wochenschr 2017; 142: 1375-1378
144 Obaid S, Weil AG, Rahme R. et al. Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Guerin therapy. Surg Neurol Int 2011; 2: 162
145 Viney K, Linh NN, Gegia M. et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. Eur Respir J 2021; 57: 2100361
146 Robert Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2020. Berlin: Robert Koch Institut; 2021
147 Robert Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2019. Berlin: Robert Koch Institut; 2020
148 Günther G, van Leth F, Alexandru S. et al. Multidrug-resistant tuberculosis in Europe, 2010–2011. Emerg Infect Dis 2015; 21: 409-416
149 Fregonese F, Ahuja SD, Akkerman OW. et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med 2018; 6: 265-275
150 Ahmad N, Ahuja SD, Akkerman OW. et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018; 392: 821-834
151 Grobbel HP, Merker M, Köhler N. et al. Design of multidrug-resistant tuberculosis treatment regimens based on DNA sequencing. Clin Infect Dis 2021;
152 Heyckendorf J, Marwitz S, Reimann M. et al. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. Eur Respir J 2021;
153 Mirzayev F, Viney K, Linh NN. et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J 2020;
154 Otto-Knapp R, Bös L, Schönfeld N. et al. Resistenzen gegen Zweitlinienmedikamente bei Migranten mit multiresistenter Tuberkulose in der Region Berlin. Pneumologie 2014; 68: 496-500
155 Lange C, Duarte R, Fréchet-Jachym M. et al. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. Am J Respir Crit Care Med 2016; 194: 1029-1031
156 European Medicines Agency. Dovprela (previously Pretomanid FGK). Stand (25.05.2022): https://www.ema.europa.eu/en/medicines/human/EPAR/pretomanid-fgk
157 Conradie F, Diacon AH, Ngubane N. et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med 2020; 382: 893-902
158 World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2022. (WHO/UCN/TB/2022.2). Licence: CC BY-NC-SA 3.0 IGO
159 Chesov D, Heyckendorf J, Alexandru S. et al. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J 2020;
160 Olaru ID, Heyckendorf J, Andres S. et al. Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. Eur Respir J 2017; 49: 1700742
161 Mokhele I, Jinga N, Berhanu R. et al. Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa. BMC Pregnancy Childbirth 2021; 21: 453
162 Gupta A, Mathad JS, Abdel-Rahman SM. et al. Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. Clin Infect Dis 2016; 62: 761-769
163 Loveday M, Hughes J, Sunkari B. et al. Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa. Clin Infect Dis 2021; 72: 1158-1168
164 Karo B, Krause G, Hollo V. et al. Impact of HIV infection on treatment outcome of tuberculosis in Europe. Aids 2016; 30: 1089-1098
165 Cerrone M, Bracchi M, Wasserman S. et al. Safety implications of combined antiretroviral and anti-tuberculosis drugs. Expert Opin Drug Saf 2020; 19: 23-41
166 British HIV Association. BHIVA guidelines for the management of tuberculosis in adults living with HIV 2018 (2021 interim uptdate). 2021
167 Schnippel K, Ndjeka N, Maartens G. et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 2018; 6: 699-706
168 Ndjeka N, Schnippel K, Master I. et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J 2018; 52
169 British HIV Association. Guidelines for the management of tuberculosis in adults living with HIV 2018 (2021 interim update). 2021
170 Borisov S, Danila E, Maryandyshev A. et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J 2019; 54
171 World Health Organisation. Active tuberculosis drug-safety monitoring and management (aDSM) – Framework for implementation. Geneva: World Health Organisation; 2015
172 Tornheim JA, Dooley KE. Tuberculosis Associated with HIV Infection. Microbiol Spectr 2017; 5
173 World Health Organization. Global tuberculosis report 2019. 2020
174 Manosuthi W, Chottanapand S, Thongyen S. et al. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43: 42-46
175 Zhou J, Elliott J, Li PC. et al. Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. BMC Infect Dis 2009; 9: 46
176 Fiebig L, Kollan C, Hauer B. et al. HIV-prevalence in tuberculosis patients in Germany, 2002-2009: an estimation based on HIV and tuberculosis surveillance data. PLoS One 2012; 7: e49111
177 European Centre for Disease Prevention and Control WROfE. Tuberculosis surveillance and monitoring in Europe 2021–2019 data. 2021
178 Batungwanayo J, Taelman H, Dhote R. et al. Pulmonary tuberculosis in Kigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis 1992; 146: 53-56
179 Jones BE, Young SM, Antoniskis D. et al. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1993; 148: 1292-1297
180 Naing C, Mak JW, Maung M. et al. Meta-analysis: the association between HIV infection and extrapulmonary tuberculosis. Lung 2013; 191: 27-34
181 Leeds IL, Magee MJ, Kurbatova EV. et al. Site of extrapulmonary tuberculosis is associated with HIV infection. Clin Infect Dis 2012; 55: 75-81
182 Burman WJ, Jones BE. Clinical and radiographic features of HIV-related tuberculosis. Semin Respir Infect 2003; 18: 263-271
183 Baciewicz AM, Chrisman CR, Finch CK. et al. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 2013; 29: 1-12
184 Niemi M, Backman JT, Fromm MF. et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-850
185 European AIDS Clinical Society (EACS). EACS Guidelines 2021. Tuberculosis. Diagnosis & Treatment of TB in PLWH. 2021
186 Daskapan A, Idrus LR, Postma MJ. et al. A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clin Pharmacokinet 2019; 58: 747-766
187 Centers for Disease Control and Prevention. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. Stand (11.10.2022): https://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/recommendations02.htm
188 European AIDS Clinical Society (EACS). ART: TB/HIV Co-infection. 2021
189 Ahmad Khan F, Minion J, Al-Motairi A. et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis 2012; 55: 1154-1163
190 Meintjes G, Brust JCM, Nuttall J. et al. Management of active tuberculosis in adults with HIV. Lancet HIV 2019; 6: e463-e474
191 Narendran G, Menon PA, Venkatesan P. et al. Acquired rifampicin resistance in thrice-weekly antituberculosis therapy: impact of HIV and antiretroviral therapy. Clin Infect Dis 2014; 59: 1798-1804
192 Uthman OA, Okwundu C, Gbenga K. et al. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163: 32-39
193 Abay SM, Deribe K, Reda AA. et al. The Effect of Early Initiation of Antiretroviral Therapy in TB/HIV-Coinfected Patients: A Systematic Review and Meta-Analysis. Journal of the International Association of Providers of AIDS Care 2015; 14: 560-570
194 Havlir DV, Kendall MA, Ive P. et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-1491
195 Abdool Karim SS, Naidoo K, Grobler A. et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706
196 Blanc FX, Sok T, Laureillard D. et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365: 1471-1481
197 Namale PE, Abdullahi LH, Fine S. et al. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol 2015; 10: 1077-1099
198 Chelkeba L, Fekadu G, Tesfaye G. et al. Effects of time of initiation of antiretroviral therapy in the treatment of patients with HIV/TB co-infection: A systemic review and meta-analysis. Ann Med Surg (Lond) 2020; 55: 148-158
199 Mfinanga SG, Kirenga BJ, Chanda DM. et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis 2014; 14: 563-571
200 Kaplan R, Hermans S, Caldwell J. et al. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town. BMC Infect Dis 2018; 18: 356
201 Torok ME, Yen NT, Chau TT. et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52: 1374-1383
202 Abdool Karim SS, Naidoo K, Grobler A. et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492-1501
203 Boulle A, Van Cutsem G, Cohen K. et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. Jama 2008; 300: 530-539
204 World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021
205 Deutsche AIDS-Gesellschaft e. V. (DAIG). Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-1-Infektion. Registernummer 055-001. AWMF. 2020
206 Grinsztejn B, De Castro N, Arnold V. et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis 2014; 14: 459-467
207 Dooley KE, Kaplan R, Mwelase N. et al. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clin Infect Dis 2020; 70: 549-556
208 Modongo C, Wang Q, Dima M. et al. Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana. J Acquir Immune Defic Syndr 2019; 82: 111-115
209 De Castro N, Marcy O, Chazallon C. et al. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial. Lancet Infect Dis 2021; 21: 813-822
210 Barcelo C, Aouri M, Courlet P. et al. Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. J Antimicrob Chemother 2019; 74: 2690-2697
211 Meintjes G, Lawn SD, Scano F. et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-523
212 Meintjes G, Wilkinson RJ, Morroni C. et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS (London, England) 2010; 24: 2381-2390
213 Meintjes G, Skolimowska KH, Wilkinson KA. et al. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2012; 186: 369-377
214 Meintjes G, Stek C, Blumenthal L. et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med 2018; 379: 1915-1925
215 World Health Organization. Active tuberculosis drug-safety monitoring and management (aDSM) Framework for implementation. 2015
216 Alffenaar JC, Gumbo T, Dooley KE. et al. Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. Clin Infect Dis 2020; 70: 1774-1780
217 Srivastava S, Pasipanodya JG, Meek C. et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-1959
218 Pasipanodya JG, Srivastava S, Gumbo T. Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy. Clin Infect Dis 2012; 55: 169-177
219 Pasipanodya JG, McIlleron H, Burger A. et al. Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes. J Infect Dis 2013; 208: 1464-1473
220 Zheng X, Bao Z, Forsman LD. et al. Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response. Clin Infect Dis 2020;
221 Naidoo A, Naidoo K, McIlleron H. et al. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. J Clin Pharmacol 2017; 57: 1369-1386
222 Smythe W, Khandelwal A, Merle C. et al. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother 2012; 56: 2091-2098
223 Azuma J, Ohno M, Kubota R. et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013; 69: 1091-1101
224 van der Burgt EP, Sturkenboom MG, Bolhuis MS. et al. End TB with precision treatment!. Eur Respir J 2016; 47: 680-682
225 Sotgiu G, Alffenaar JW, Centis R. et al. Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. Int J Infect Dis 2015; 32: 101-104
226 Märtson AG, Burch G, Ghimire S. et al. Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol 2021; 17: 23-39
227 Magis-Escurra C, Later-Nijland HMJ, Alffenaar JWC. et al. Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Int J Antimicrob Agents 2014; 44: 229-234
228 van den Elsen SHJ, Sturkenboom MGG, Akkerman OW. et al. Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. Antimicrob Agents Chemother 2019; 63: e00384-19
229 van den Elsen SHJ, Sturkenboom MGG, Vanʼt Boveneind-Vrubleuskaya N. et al. Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. Antimicrob Agents Chemother 2018; 62: e01092-18
230 Kamp J, Bolhuis MS, Tiberi S. et al. Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. Int J Antimicrob Agents 2017; 49: 688-694
231 Dijkstra JA, van Altena R, Akkerman OW. et al. Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis. Int J Antimicrob Agents 2015; 46: 332-337
232 Aarnoutse RE, Sturkenboom MGG, Robijns K. et al. An interlaboratory quality control programme for the measurement of tuberculosis drugs. Eur Respir J 2015; 46: 268-271
233 Tonko S, Baty F, Brutsche MH. et al. Length of hospital stay for TB varies with comorbidity and hospital location. Int J Tuberc Lung Dis 2020; 24: 948-955
234 Migliori GB, Visca D, van den Boom M. et al. Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology 2021; 27: 248-256
235 Diel R, Nienhaus A. Cost of illness of non-multidrug-resistant tuberculosis in Germany: an update. ERJ Open Res 2020; 6
236 Diel R, Rutz S, Castell S. et al. Tuberculosis: cost of illness in Germany. Eur Respir J 2012; 40: 143-151
237 Vogl M. Assessing DRG cost accounting with respect to resource allocation and tariff calculation: the case of Germany. Health Econ Rev 2012; 2: 15
238 Diel R, Nienhaus A, Lampenius N. et al. Cost of multi drug resistance tuberculosis in Germany. Respir Med 2014; 108: 1677-1687
239 Diel R, Hittel N, Schaberg T. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany. Respir Med 2015; 109: 632-641
240 Schwabe U, Paffrath D. Arzneiverordnungs-Report 2015. 1. Aufl.. Berlin-Heidelberg: Springer-Verlag; 2015
241 Diel R, Sotgiu G, Andres S. International Society for Infectious Diseases. et al. Cost of multidrug resistant tuberculosis in Germany – An update. IJID 2021; 103: 102-109
242 World Health Organization. A patient centred approach to TB care. 2019
243 Si Z-L, Kang L-L, Shen X-B. et al. Adjuvant Efficacy of Nutrition Support During Pulmonary Tuberculosis Treating Course: Systematic Review and Meta-analysis. Chin Med J 2015; 128: 3219-3230
244 Ganmaa D, Uyanga B, Zhou X. et al. Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. N Engl J Med 2020; 383: 359-368
245 Aibana O, Huang CC, Aboud S. et al. Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis. PLoS Med 2019; 16: e1002907
246 Kaufmann SHE, Lange C, Rao M. et al. Progress in tuberculosis vaccine development and host-directed therapies – a state of the art review. Lancet Respir Med 2014; 2: 301-320
247 Linseisen J, Bechthold A, Bischoff-Ferrari HA. et al. Vitamin D und Prävention ausgewählter chronischer Krankheiten. Bonn: Deutsche Gesellschaft für Ernährung e. V. (DGE); 2011
248 Peltzer K, Naidoo P, Matseke G. et al. Prevalence of post-traumatic stress symptoms and associated factors in tuberculosis (TB), TB retreatment and/or TB–HIV co-infected primary public health-care patients in three districts in South Africa. Psychol Health Med 2013; 18: 387-397
249 Loddenkemper R, Brönnecke M, Castell S. et al. Tuberkulose und Rauchen. Pneumologie 2016; 70: 17-22
250 Wang EY, Arrazola RA, Mathema B. et al. The impact of smoking on tuberculosis treatment outcomes: a meta-analysis. Int J Tuberc Lung Dis 2020; 24: 170-175
251 van Zyl Smit RN, Pai M, Yew WW. et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 2010; 35: 27-33
252 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S3-Leitlinie „Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung“. 2021 Gültig bis 31.12.2025
253 Yablonski P, Cordos I, Sokolovich E. et al. Surgical treatment of pulmonary tuberculosis. Eur Respir Monogr 2013; 61: 20-36
254 Halezeroglu S, Okur E. Thoracic surgery for haemoptysis in the context of tuberculosis: what is the best management approach?. J Thorac Dis 2014; 6: 182-185
255 Farid S, Mohamed S, Devbhandari M. et al. Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence -- a National Centreʼs experience. J Cardiothorac Surg 2013; 8: 180
256 Sagan D, Gozdziuk K. Surgery for pulmonary aspergilloma in immunocompetent patients: no benefit from adjuvant antifungal pharmacotherapy. Ann Thorac Surg 2010; 89: 1603-1610
257 Allwood BW, Byrne A, Meghji J. et al. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge. Respiration 2021; 100: 751-763
258 Allwood BW, van der Zalm MM, Amaral AFS. et al. Post-tuberculosis lung health: perspectives from the First International Symposium. Int J Tuberc Lung Dis 2020; 24: 820-828
259 Datta S, Gilman RH, Montoya R. et al. Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study. Eur Respir J 2020; 56: 1900495
260 Connor S, Foley K, Harding R. et al. Declaration on palliative care and MDR/XDR-TB. Int J Tuberc Lung Dis 2012; 16: 712-713
261 Muñoz-Torrico M, Cid-Juárez S, Gochicoa-Rangel L. et al. Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2020; 24: 700-705
262 Allwood BW, Stolbrink M, Baines N. et al. Persistent chronic respiratory symptoms despite TB cure is poorly correlated with lung function. Int J Tuberc Lung Dis 2021; 25: 262-270
263 Migliori GB, Marx FM, Ambrosino N. et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis 2021; 25: 797-813
264 Weatherall M, Marsh S, Shirtcliffe P. et al. Quality of life measured by the St Georgeʼs Respiratory Questionnaire and spirometry. Eur Respir J 2009; 33: 1025-1030
265 Bundesärztekammer (BÄK) KBK, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie COPD – Teilpublikation der Langfassung, 2. Aufl. Version 1.; Zugriff: 26.08.2021.
266 da Rocha NS, Power MJ, Bushnell DM. et al. The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF. Value Health 2012; 15: 449-457
267 Krakauer EL, Dheda K, Kalsdorf B. et al. Palliative care and symptom relief for people affected by multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2019; 23: 881-890
268 World Health Organization Regional Office for Europe. Review on palliative care with focus on 18 high tuberculosis priority countries. 2021
269 Schönfeld N, Otto-Knapp R, Häcker B. et al. Palliative Care in der pneumologischen Infektiologie. Atemwegs- und Lungenkrankheiten 2020; 46: 408-413
270 Lange C, Aarnoutse RE, Alffenaar JWC. et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2019; 23: 645-662
271 World Health Organization Regional Office for Europe. Roadmap to Prevent and Combat Drug-resistant Tuberculosis. Kopenhagen: World Health Organization, Regional Office for Europe; 2011
272 Harding R, Foley KM, Connor SR. et al. Palliative and end-of-life care in the global response to multidrug-resistant tuberculosis. Lancet Infect Dis 2012; 12: 643-646
273 Migliori GB, Wu SJ, Matteelli A. et al. Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 2022; 26: 190-205
274 Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976; 19: 1-63
275 Kritski AL, Marques MJ, Rabahi MF. et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 153: 331-335
276 Shea KM, Kammerer JS, Winston CA. et al. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol 2014; 179: 216-225
277 Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med 2001; 345: 189-200
278 Diel R, Loddenkemper R, Meywald-Walter K. et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-1170
279 Diel R, Loddenkemper R, Zellweger J-P. et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801
280 Petruccioli E, Scriba TJ, Petrone L. et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur Respir J 2016; 48: 1751-1763
281 Pai M, Behr MA, Dowdy D. et al. Tuberculosis. Nat Rev Dis Primers 2016; 2: 16076
282 Fachinformation Tuberkulin PPD RT23 SSI. In: AJ Vaccines ed. 2018 Stand (11.10.2022): https://ajvaccines.com/wp-content/uploads/2021/05/Tuberculin-PPD-RT23-AJV_SmPC.pdf
283 Sloot R, Schim van der Loeff MF, Kouw PM. et al. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 2014; 190: 1044-1052
284 Krutikov M, Faust L, Nikolayevskyy V. et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. Lancet Infect Dis 2022; 22: 250-264
285 World Health Organization. Rapid communication: TB antigen-based skin tests for the diagnosis of TB infection. Geneva: World Health Organization; 2022. (WHO/UCN/TB/2022.1). Licence: CC BY-NC-SA 3.0 IGO
286 Campbell JR, Winters N, Menzies D. Absolute risk of tuberculosis among untreated populations with a positive tuberculin skin test or interferon-gamma release assay result: systematic review and meta-analysis. BMJ 2020; 368: m549
287 Sester M, van Crevel R, Leth F. et al. Numbers needed to treat to prevent tuberculosis. Eur Respir J 2015; 46: 1836-1838
288 Noubiap JJ, Nansseu JR, Nyaga UF. et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis. Lancet Glob Health 2019; 7: e448-e460
289 Dash LA, Comstock GW, Flynn JP. Isoniazid preventive therapy: Retrospect and prospect. Am Rev Respir Dis 1980; 121: 1039-1044
290 Snow K, Bekker A, Huang G. et al. Tuberculosis in pregnant women and neonates: A meta-review of current evidence. Paediatr Respir Rev 2020; 36: 27-32
291 World Health Organization. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. Geneva: World Health Organization; 2020
292 Smieja MJ, Marchetti CA, Cook DJ. et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000;
293 Akolo C, Adetifa I, Shepperd S. et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010;
294 Sterling TR, Njie G, Zenner D. et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020; 69: 1-11
295 Gupta RK, Calderwood CJ, Yavlinsky A. et al. Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. Nat Med 2020; 26: 1941-1949
296 Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat Rev Microbiol 2018; 16: 80-90
297 van Halsema CL, Okhai H, Hill T. et al. Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom. Aids 2020; 34: 1813-1821
298 Lin AW, Lau SK, Woo PC. Screening and treatment of latent tuberculosis infection among HIV-infected patients in resource-rich settings. Expert Rev Anti Infect Ther 2016; 14: 489-500
299 Elzi L, Schlegel M, Weber R. et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102
300 Golub JE, Cohn S, Saraceni V. et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis 2015; 60: 639-645
301 Karo B, Haas W, Kollan C. et al. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis 2014; 14: 148
302 Karo B, Krause G, Castell S. et al. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy. BMC Infect Dis 2017; 17: 517
303 Rangaka MX, Wilkinson KA, Glynn JR. et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45-55
304 Petruccioli E, Chiacchio T, Navarra A. et al. Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. J Infect 2020; 80: 536-546
305 Doan TN, Eisen DP, Rose MT. et al. Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis. PLoS One 2017; 12: e0188631
306 Rubbert-Roth A, Burmester GR, Dörner T. et al. [Recommendations for use of rituximab in patients with rheumatoid arthritis]. Z Rheumatol 2014; 73: 165-174
307 Bittner S, Engel S, Lange C. et al. [Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany]. Nervenarzt 2019; 90: 1245-1253
308 Mikulska M, Lanini S, Gudiol C. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 2018; 24 (Suppl. 02) S71-S82
309 Cantini F, Nannini C, Niccoli L. et al. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators Inflamm 2017; 2017: 8909834
310 Edwards A, Gao Y, Allan RN. et al. Corticosteroids and infliximab impair the performance of interferon-gamma release assays used for diagnosis of latent tuberculosis. Thorax 2017; 72: 946-949
311 Mow WS, Abreu-Martin MT, Papadakis KA. et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-313
312 Lorenz HM, Kneitz C. [Infections]. Z Rheumatol 2019; 78: 236-242
313 Sester M, van Leth F, Bruchfeld J. et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014; 190: 1168-1176
314 Bettelli F, Giusti D, Morselli M. et al. Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study. Ann Hematol 2020; 99: 2201-2203
315 Cheng MP, Kusztos AE, Bold TD. et al. Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation. Clin Infect Dis 2019; 69: 869-872
316 Anibarro L, Pena A. Tuberculosis in patients with haematological malignancies. Mediterr J Hematol Infect Dis 2014; 6: e2014026
317 Silva FA, Matos JO, de Q Mello FC. et al. Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances. Haematologica 2005; 90: 1110-1115
318 Agrawal N, Aggarwal M, Kapoor J. et al. Incidence and clinical profile of tuberculosis after allogeneic stem cell transplantation. Transpl Infect Dis 2018; 20
319 Lee HJ, Lee DG, Choi SM. et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. PLoS One 2017; 12: e0173250
320 Fan WC, Liu CJ, Hong YC. et al. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. Int J Tuberc Lung Dis 2015; 19: 58-64
321 Torre-Cisneros J, Doblas A, Aguado JM. et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48: 1657-1665
322 Klote MM, Agodoa LY, Abbott K. Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the United States, 1998–2000. Am J Transplant 2004; 4: 1523-1528
323 Kristensen KL, Ravn P, Petersen JH. et al. Long-term risk of tuberculosis among migrants according to migrant status: a cohort study. Int J Epidemiol 2020; 49: 776-785
324 Aldridge RW, Zenner D, White PJ. et al. Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519 955 migrants screened before entry to England, Wales, and Northern Ireland. Lancet 2016; 388: 2510-2518
325 van den Boogaard J, Slump E, Schimmel HJ. et al. High Incidence of Active Tuberculosis in Asylum Seekers from Eritrea and Somalia in the First 5 Years after Arrival in the Netherlands. Emerg Infect Dis 2020; 26: 675-681
326 Neuhann F, Franek H, Funke N. et al. Kontaktuntersuchungen bei aktiver Tuberkulose und Management latenter Tuberkulose: 5 Jahres-Analyse an einem deutschen Großstadt Gesundheitsamt. Gesundheitswesen 2020; 82: 260-266
327 World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018
328 Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009; 48: 72-82
329 Pape S, Groß F, Ulrichs T. Die Tuberkulosesituation im Berliner Justizvollzug 2011–2016 – Eine Folgeerhebung. Bundesgesundheitsblatt– Gesundheitsforschung – Gesundheitsschutz 2019; 62: 893-903
330 Bamrah S, Yelk Woodruff RS, Powell K. et al. Tuberculosis among the homeless, United States, 1994–2010. Int J Tuberc Lung Dis 2013; 17: 1414-1419
331 Binswanger IA, OʼBrien K, Benton K. et al. Tuberculosis testing in correctional officers: a national random survey of jails in the United States. Int J Tuberc Lung Dis 2010; 14: 464-470
332 Mack U, Migliori GB, Sester M. et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-973
333 Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 1999; 3: 847-850
334 Getahun H, Matteelli A, Abubakar I. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46: 1563-1576
335 Stagg HR, Zenner D, Harris RJ. et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 2014; 161: 419-428
336 Swindells S, Ramchandani R, Gupta A. et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med 2019; 380: 1001-1011
337 Menzies D, Adjobimey M, Ruslami R. et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med 2018; 379: 440-453
338 Sterling TR, Villarino ME, Borisov AS. et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166
339 Colangeli R, Arcus VL, Cursons RT. et al. Whole genome sequencing of Mycobacterium tuberculosis reveals slow growth and low mutation rates during latent infections in humans. PLoS One 2014; 9: e91024
340 Ford CB, Lin PL, Chase MR. et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011; 43: 482-486
341 Magdorf K, Bialek R, Detjen A. Tuberkulose und nicht tuberkulöse mykobakterielle Krankheiten. Deutsche Gesellschaft für Pädiatrische Infektiologie (DGPI). Infektionen bei Kindern und Jugendlichen. Stuttgart: Thieme; 2009
342 Centers for Disease Control and Prevention. Latent Tuberculosis Infection: A Guide For Primary Health Care Providers. Atlanta: CDC; 2013
343 Leung CC, Rieder HL, Lange C. et al. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011; 37: 690-711
344 Marks SM, Mase SR, Morris SB. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis 2017; 64: 1670-1677
345 Migliori GB, Tiberi S, Zumla A. et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis 2020; 92S: S15-S25
346 Sobhy S, Babiker Z, Zamora J. et al. Maternal and perinatal mortality and morbidity associated with tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis. BJOG 2017; 124: 727-733
347 Sterling TRNG, Zenner D. et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020; 2020: 1-11
348 Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49: 1-51
349 Centers for Disease Control and Prevention. Latent Tuberculosis Infection: A Guide for Primary Health Care Providers. Atlanta: CDC; 2020
350 Cohn DL. Treatment of latent tuberculosis infection: renewed opportunity for tuberculosis control. Clin Infect Dis 2000; 31: 120-124
351 Gupta A, Nayak U, Ram M. et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis 2007; 45: 241-249
352 Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis 2012; 55: 1532-1549
353 AWMF-Leitlinie: HIV-Therapie in der Schwangerschaft und bei HIV-exponierten Neugeborenen. AWMF-Registernummer 055-002, Stand 11.09.2020
354 Malhame I, Cormier M, Sugarman J. et al. Latent Tuberculosis in Pregnancy: A Systematic Review. PLoS One 2016; 11: e0154825
355 Seidler A, Nienhaus A, Diel R. Review of epidemiological studies on the occupational risk of tuberculosis in low-incidence areas. Respiration 2005; 72: 431-446
356 Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63-75
357 Bundesgesetzblatt I, S. 1082, 18. Dezember 2008 (BGBl. I S. 2768), die zuletzt durch Artikel 1 der Verordnung vom 12. Juli 2019 (BGBl. I S. 1082) geändert worden ist.
358 Nienhaus A, Schablon A, Bacle CL. et al. Evaluation of the interferon-gamma release assay in healthcare workers. Int Arch Occup Environ Health 2008; 81: 295-300
359 Hermes L, Kersten JF, Nienhaus A. et al. Risk Analysis of Latent Tuberculosis Infection among Health Workers Compared to Employees in Other Sectors. Int J Environ Res Public Health 2020; 17: 4643
360 Schablon A, Nienhaus A, Ringshausen FC. et al. Occupational screening for tuberculosis and the use of a borderline zone for interpretation of the IGRA in German healthcare workers. PloS one 2014; 9: e115322
361 Torres Costa J, Silva R, Ringshausen FC. et al. Screening for tuberculosis and prediction of disease in Portuguese healthcare workers. J Occup Med Toxicol 2011; 6: 19
362 Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001
363 Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 49: 1883-1889
364 Menzies D, Long R, Trajman A. et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697
365 Aspler A, Long R, Trajman A. et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax 2010; 65: 582-587
366 Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40: 670-676
367 Schaberg T, Bauer T, Castell S. et al. Empfehlungen zur Therapie, Chemoprävention und Chemoprophylaxe der Tuberkulose im Erwachsenen- und Kindesalter. Pneumologie 2012; 66: 133-171
368 Horwitz O, Payne PG, Wilbek E. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ 1966; 35: 509-526
369 Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967; 95: 935-943
370 Comstock GW, Baum C, Snider DE. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979; 119: 827-830
371 Johnson JL, Okwera A, Hom DL. et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS (London, England) 2001; 15: 2137-2147
372 Marx FM, Dunbar R, Enarson DA. et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis 2014; 58: 1676-1683
373 Drew BJ, Ackerman MJ, Funk M. et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047-1060
374 Dooley KE, Rosenkranz SL, Conradie F. et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis 2021; 21: 975-983
375 Brust JCM, Gandhi NR, Wasserman S. et al. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study. Clin Infect Dis 2021; 73: 2083-2092
376 Maurer FP, Bauer T, Diel R. et al. Gemeinsame Stellungnahme zur neuen Empfehlung der WHO zur Behandlung der multiresistenten und Rifampicin-resistenten Tuberkulose. Pneumologie 2019; 73: 270-273
377 van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 2014; 69: 2310-2318
378 Alffenaar JC, Akkerman OW, Tiberi S. et al. Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?. Eur Respir J 2020; 55: 1901908
379 World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva: World Health Organization; 2014
380 Häcker B, Schönfeld N, Krieger D. et al. Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany. Eur Respir J 2020;
381 Mohr E, Hughes J, Reuter A. et al. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. Eur Respir J 2018; 51: 1800017
382 Sasahara K, Shimokawa Y, Hirao Y. et al. Pharmacokinetics and Metabolism of Delamanid, a Novel Anti-Tuberculosis Drug, in Animals and Humans: Importance of Albumin Metabolism In Vivo. Drug Metab Dispos 2015; 43: 1267-1276
383 Russo PACM. Toxic optic neuropathy associated with ethambutol: implications for current therapy. J Am Optom Assoc 1994; 65: 332-338
384 Tiberi S, Payen MC, Sotgiu G. et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 2016; 47: 1235-1243
385 De Lorenzo S, Alffenaar JW, Sotgiu G. et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392
386 Sotgiu G, D'Ambrosio L, Centis R. et al. Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review. Int J Mol Sci 2016; 17: 373
387 Tiberi S, Sotgiu G, DʼAmbrosio L. et al. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 2016; 47: 1758-1766
388 Lange C, Abubakar I, Alffenaar JW. et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63
389 Clinical and Laboratory Standards Institute. Supplement M 24 – Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. 3rd Edition. 2020. Stand (16.10.2022): https://clsi.org/standards/products/microbiology/documents/m24/
390 Bottger EC. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 2011; 17: 1128-1134
391 Peloquin CA, Namdar R, Dodge AA. et al. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3: 703-710
392 Du H, Chen X, Fang Y. et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep 2013; 40: 3591-3596
393 Wang PY, Xie SY, Hao Q. et al. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2012; 16: 589-595
394 Azuma J, Ohno M, Kubota R. et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013; 69: 1091-1101
395 Bothahemley G. Drug treatment for tuberculosis during pregnancy: safety. Drug Saf 2001; 24: 553-565
396 Helgren ME, Cliffer KD, Torrento K. et al. Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy. J Neurosci 1997; 17: 372-382
397 Douros A, Grabowski K, Stahlmann R. Safety issues and drug-drug interactions with commonly used quinolones. Expert Opin Drug Metab Toxicol 2015; 11: 25-39
398 Lee M, Lee J, Carroll MW. et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518
399 Sotgiu G, Centis R, DʼAmbrosio L. et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442
400 Zhang X, Falagas ME, Vardakas KZ. et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 2015; 7: 603-615
401 Koh W-JKO, Gwak H, Chung JW. et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391
402 Diacon AH, De Jager VR, Dawson R. et al. Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis. Antimicrob Agents Chemother 2020; 64: e02012-19
403 Srivastava S, Magombedze G, Koeuth T. et al. Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. Antimicrob Agents Chemother 2017; 61: e00751-17
404 Wasserman S, Brust JCM, Abdelwahab MT. et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother 2022; 77: 1146-1154
405 Payen MC, Muylle I, Vandenberg O. et al. Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases. Int J Tuberc Lung Dis 2018; 22: 34-39
406 Weiner M, Burman W, Luo CC. et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007; 51: 2861-2866
407 Nijland HM, Ruslami R, Suroto AJ. et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45: 1001-1007
408 Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-854
409 World Health Organization. Updated critical concentrations for first-line and second-line DST (as of May 2012). 2012
410 World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Licence: CC BY-NC-SA 3.0 IGO. 2018
411 Clinical and Laboratory Standards Institute. Supplement M 62 – Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. 1. Aufl.. 2018. Stand (16.10.2022): https://clsi.org/media/2626/m62ed1_sample.pdf
412 Brennan JPYD. Handbook of anti-tuberculosis agents. Introduction. Tuberculosis (Edinb) 2008; 88: 85-86
413 World Health Organization. Technical report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine). Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO
414 Dorman SE, Nahid P, Kurbatova EV. et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384: 1705-1718
415 Williams DL, Spring L, Collins L. et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 1853-1857
416 Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40: 327-341
417 Sterling TR, Moro RN, Borisov AS. et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis 2015; 61: 527-535
418 Nakatani Y, Opel-Reading HK, Merker M. et al. Role of Alanine Racemase Mutations in Mycobacterium tuberculosis d-Cycloserine Resistance. Antimicrob Agents Chemother 2017; 61: e01575-17